Buy TEM by Sep 26, 2026.

First and foremost, the company is still operating at a loss, but its revenue growth momentum is very strong (according to the latest filings, the most recent year over year growth rate is approximately 70%–80%). The business operates at the intersection of artificial intelligence and healthcare data, focusing primarily on precision medicine and large scale clinical datasets. However, after a strong rally following its initial public offering (IPO), TEM is currently stabilizing. The price action has been range bound for …